NASDAQ:AGRX Agile Therapeutics (AGRX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AGRX Stock Alerts $0.33 -0.04 (-10.81%) (As of 10:08 AM ET) Add Compare Share Share Today's Range$0.32▼$0.4150-Day Range$0.33▼$1.6052-Week Range$0.20▼$12.15Volume100,068 shsAverage Volume745,379 shsMarket Capitalization$976,800.00P/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Agile Therapeutics alerts: Email Address Agile Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2,444.9% Upside$8.50 Price TargetShort InterestBearish12.68% of Float Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment0.18Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 stars 3.3 Analyst's Opinion Consensus RatingAgile Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Agile Therapeutics has a forecasted upside of 2,444.9% from its current price of $0.33.Amount of Analyst CoverageAgile Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.68% of the float of Agile Therapeutics has been sold short.Short Interest Ratio / Days to CoverAgile Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agile Therapeutics has recently increased by 62.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAgile Therapeutics does not currently pay a dividend.Dividend GrowthAgile Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agile Therapeutics is -1.59. Previous Next 2.3 News and Social Media Coverage News SentimentAgile Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Agile Therapeutics this week, compared to 1 article on an average week.Search Interest13 people have searched for AGRX on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agile Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.50% of the stock of Agile Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 10.92% of the stock of Agile Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Agile Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agile Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Agile Therapeutics Stock (NASDAQ:AGRX)Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.Read More AGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGRX Stock News HeadlinesMarch 28, 2024 | globenewswire.comAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate UpdateMarch 26, 2024 | msn.comWhy Agile Therapeutics (AGRX) Stock Is Down 60%March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 26, 2024 | finanznachrichten.deAgile Therapeutics, Inc.: Agile Therapeutics Announces Delisting from NasdaqMarch 25, 2024 | globenewswire.comAgile Therapeutics Announces Delisting from NasdaqMarch 23, 2024 | benzinga.comLatest News for Agile Therapeutics Stock (NASDAQ:AGRX)March 21, 2024 | markets.businessinsider.comAgile Therapeutics is about to announce its earnings — here's what to expectMarch 21, 2024 | benzinga.comAgile Therapeutics's Earnings: A PreviewMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | globenewswire.comCorrection - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024March 21, 2024 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Rating Lowered to Sell at StockNews.comMarch 20, 2024 | globenewswire.comAgile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024March 19, 2024 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Receives Hold Rating from Maxim GroupMarch 13, 2024 | msn.comAgile Therapeutics stock soars on complete debt payoffMarch 13, 2024 | globenewswire.comAgile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan ExecutionFebruary 24, 2024 | investing.comAgile Therapeutics reduces warrant exercise priceFebruary 22, 2024 | benzinga.comAgile Therapeutics Stock (NASDAQ:AGRX), Short Interest ReportFebruary 22, 2024 | benzinga.comWhat's Going On With Women Health Focused Agile Therapeutics Stock Today?February 22, 2024 | finance.yahoo.comAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross ProceedsFebruary 22, 2024 | investorplace.comWhy Is Agile Therapeutics (AGRX) Stock Up 87% Today?February 22, 2024 | globenewswire.comAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross ProceedsFebruary 22, 2024 | investorplace.comWhy Is Agile Therapeutics (AGRX) Stock Up 87% Today?February 15, 2024 | msn.comAgile Therapeutics reports higher prelim FY revenue than last yearFebruary 15, 2024 | finance.yahoo.comAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance UpdateFebruary 15, 2024 | globenewswire.comAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement & Provides Performance UpdateJanuary 25, 2024 | markets.businessinsider.comBuy Rating for Agile Therapeutics: Regulatory Tailwinds and Strong Sales Growth ForecastJanuary 23, 2024 | finance.yahoo.comThe Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without CostSee More Headlines Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today3/28/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,444.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($13.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,410,000.00 Net Margins-69.73% Pretax Margin-69.73% Return on EquityN/A Return on Assets-188.07% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.44 Sales & Book Value Annual Sales$10.88 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value($6.83) per share Price / Book-0.05Miscellaneous Outstanding Shares2,960,000Free Float2,949,000Market Cap$988,640.00 OptionableNot Optionable Beta1.51 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Alfred F. Altomari (Age 65)Chairman, President & CEO Comp: $644.4kMr. Geoffrey P. Gilmore (Age 58)Senior VP & Chief Administrative Officer Comp: $478.92kDr. Paul Korner M.B.A. (Age 58)M.D., Senior VP & Chief Medical Officer Comp: $480.4kMr. Scott M. Coiante (Age 57)CFO, Senior VP & Treasurer Comp: $520.45kMatthew RileyHead of Investor Relations & Corporate CommunicationsMr. Robert G. Conway M.E. (Age 66)Senior VP and Chief Corporate Planning & Supply Chain Officer Comp: $444.11kMs. Amy Welsh (Age 53)Senior VP & Chief Commercial Officer More ExecutivesKey CompetitorsChina PharmaNYSE:CPHIInVivo TherapeuticsNASDAQ:NVIVBluejay DiagnosticsNASDAQ:BJDXSciSparcNASDAQ:SPRCTC BiopharmNASDAQ:TCBPView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 20,477 shares on 3/11/2024Ownership: 0.691%Vanguard Group Inc.Bought 20,477 shares on 2/15/2024Ownership: 0.692%Armistice Capital LLCBought 10,000 shares on 2/13/2024Ownership: 3.649%View All Institutional Transactions AGRX Stock Analysis - Frequently Asked Questions Should I buy or sell Agile Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks. What is Agile Therapeutics' stock price target for 2024? 2 brokerages have issued 1 year price objectives for Agile Therapeutics' stock. Their AGRX share price targets range from $5.00 to $12.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 2,444.9% from the stock's current price. View analysts price targets for AGRX or view top-rated stocks among Wall Street analysts. How have AGRX shares performed in 2024? Agile Therapeutics' stock was trading at $1.95 at the start of the year. Since then, AGRX stock has decreased by 82.9% and is now trading at $0.3340. View the best growth stocks for 2024 here. Are investors shorting Agile Therapeutics? Agile Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 361,300 shares, an increase of 62.7% from the February 29th total of 222,100 shares. Based on an average daily volume of 698,200 shares, the days-to-cover ratio is currently 0.5 days. Approximately 12.7% of the shares of the stock are short sold. View Agile Therapeutics' Short Interest. When is Agile Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AGRX earnings forecast. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) posted its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to analysts' expectations of $1.49 million. During the same quarter in the prior year, the firm earned ($7.20) earnings per share. When did Agile Therapeutics' stock split? Shares of Agile Therapeutics reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX). Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (3.65%), Vanguard Group Inc. (0.69%), Vanguard Group Inc. (0.69%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Agile Therapeutics? Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AGRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.